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Introduction
Cerebral vasospasms after subarachnoid hemorrhage
(SAH) have been studied from various aspects, which is a
poor outcome resulting from SAH with a ruptured cerebral
aneurysm. For example, it has been reported that sympto-
matic patients had higher cerebrospinal fluid (CSF) levels
of interleukin-6 and interleukin-8 than asymptomatic
patients [1,2], and nitrites/nitrate increased in the CSF in
SAH patients [3,4].
Previous studies showed that C-type natriuretic peptide
(CNP) is the primary active natriuretic peptide in the
ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; CNP = C-type natriuretic peptide; CSF = cerebrospinal fluid; NO = nitric oxide;
SAH = subarachnoid hemorrhage.
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Abstract
Background: Cerebral vasospasm is a poor resulting outcome of a ruptured cerebral aneurysm; to
clarify the mechanism of vasospasm it is important to improve this outcome. C-type natriuretic peptide
(CNP) is present in the brain as a cerebral vasodilator; it is also an endothelium-derived relaxing factor
produced via cGMP. We speculated that CNP might be an inhibitor of cerebral vasospasm after
subarachnoid hemorrhage (SAH).
Methods: To clarify the role of CNP in cerebral vasospasm after SAH, we conducted 1 week
monitoring of CNP concentrations in the plasma and cerebrospinal fluid (CSF) of 26 patients who had
undergone clipping within 24 hours of the occurrence of SAH, and divided them into group A (positive
for angiographic spasm) and group B (negative for angiographic spasm). We also examined CNP
concentrations in the CSF of patients who were receiving spinal anesthesia for small orthopedic
operations, as reference patients.
Results: The CNP concentration in the CSF on day 1 was higher than in the reference patients and
decreased in both test groups, but we did not observe any significant difference between the groups.
CNP concentrations in the plasma did not change in either group.
Conclusions: CNP concentrations in the CSF were high in the acute phase after SAH, whereas
plasma CNP concentrations remained constant. However, our findings did not support our hypothesis
because we did not find any relationship between vasospasm and changes in CNP concentrations in
the CSF.
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human brain; CNP is also considered to be an endothe-
lium-derived relaxant factor, which acts in the same way as
nitric oxide (NO) [5,6]. On the basis of these previous
findings, we assumed that CNP might have vasodilator
effects to inhibit vasospasm after SAH, and conducted the
present study to determine the relationship between the
changes in CNP with cerebral vasospasm after SAH.
Patients and methods
This study was approved by an ethical committee of our
university, and we obtained informed consent for enrolled
patients, including those patients used as a reference.
Twenty-six patients with SAH due to aneurysm rupture
were included in the study after aneurysm clipping
within 24 hours of onset. Patients with chronic heart
failure (history) or renal diseases (a serum creatinine
level of more than 5.0 mg/dl) were excluded from this
study. Postoperative hyperdynamic therapy was given,
aiming at a central venous pressure or a mean right
atrial pressure of 100–150 mmHg, a mean arterial pres-
sure of 100–120 mmHg and a hematocrit of 36–40%
from day 3. Intravenous nicardipine hydrochloride
(60–80 mg/day) was given from day 1, and angiography
was undertaken to monitor the occurrence of
vasospasms from days 5–7 of hospitalization. An inde-
pendent neurosurgeon established cerebral vasospasm
as graded in the Kasselis classification (moderate and
severe were recognized as spasm) [7]. They were
divided into group A (positive for angiographic spasm)
and group B (negative for angiographic spasm).
We performed angiography several times as required, and
classified the patients according to the angiographic find-
ings from days 5–7.
Table 1 summarizes the characteristics of group A
patients. They were 53.8 ± 7.6 (mean ± SD) years of age.
Vasospasm was confirmed angiographically in 16 of the
26 patients. Outcomes were evaluated by using the
Glasgow Outcome Scale on day 30 of hospitalization.
Table 2 summarizes the characteristics of group B. Their
age (mean ± SD) was 59.3 ± 14.6 years.
CNP concentrations in the plasma and CSF were mea-
sured on days 1, 3 and 7 of hospitalization. Blood samples
were obtained with a radial arterial catheter and were cen-
trifuged at 4°C. Plasma was separated, frozen immediately
and stored at –20°C until analysis. CSF samples were
obtained with a cisternal drain or ventricular drain inserted
during surgery. After the removal of blood from the
sample, the CSF was stored at –20°C until analysis.
CNP immunoactivity was determined with a double anti-
body radioimmunoassay with RIK 9030 kit (Peninsula Lab-
Table 1
Characteristics of patients in group A
No. Age Sex WFNS Fisher Location of AN Outcome
1 46 F 4 4 R-MCA VS
2 43 M 2 3 L-AcomA VS
3 47 F 2 2 L-AcomA GR
4 51 M 2 3 R-AcomA VS
5 60 F 2 4 L-AcomA GR
6 50 F 2 4 L-AcomA D
7 48 F 2 2 L-MCA GR
8 73 M 3 3 R-ICPC D
9 67 F 4 4 L-AcomA VS
10 64 F 2 2 L-AcomA GR
11 60 F 4 3 R-MCA VS
12 63 F 5 4 L-MCA GR
13 54 M 4 3 L-ICPC GR
14 64 F 2 3 R-MCA VS
15 64 M 3 3 L-AcomA D
16 71 F 4 4 R-MCA GR
Outcome was evaluated with the Glasgow Outcome Scale. Mean age
(± SD) was 53.8 ± 7.6 years. AN, aneurysm; AcomA, anterior
communicating artery; D, death; ICPC, internal carotid-posterior
communicating artery; GR, good recovery; MCA, middle cerebral
artery; MD, moderate disability; SD, severe disability; VS, vegetative
state; WFNS, World Federation of Neurosurgical Societies SAH
grade.
Table 2
Characteristics of patients in group B
No. Age Sex WFNS Fisher Location of AN Outcome
1 64 F 3 3 R-ICPC GR
2 56 M 2 2 L-ICPC GR
3 32 F 3 2 L-AcomA GR
4 50 F 2 2 BA GR
5 75 F 5 4 L-ICPC D
6 58 F 3 4 L-MCA GR
7 67 M 3 3 BA GR
8 81 F 5 4 R-MCA VS
9 51 F 1 2 L-AcomA GR
10 72 F 3 3 R-MCA GR
Outcome was evaluated with the Glasgow Outcome Scale. Mean age
(± SD) was 59.3 ± 14.6 years. AN, aneurysm; AcomA, anterior
communicating artery; BA, basilar artery; D, death; ICPC, internal
carotid-posterior communicating artery; GR, good recovery; MCA,
middle cerebral artery; VS, vegetative state; WFNS, World Federation
of Neurosurgical Societies SAH grade.p
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oratories Inc, San Carios, CA, USA) [8]. To obtain refer-
ence data, 1–2 ml of CSF was sampled from 20 patients
who were receiving spinal block anesthesia for small
orthopedic operations. CSF sampling from the reference
patients was conducted only at surgery.
Data are expressed as means ± SD. Statistical analysis
was performed with an analysis of variance. P values of
less than 0.05 were considered statistically significant.
Results
CNP concentrations in plasma and CSF are presented in
Tables 3 and 4. Plasma concentrations are in the normal
ranges and did not change significantly within the first
week after the onset of SAH. We also did not observe any
significant difference between the groups.
The CNP level in the CSF of twelve patients of group A
and eight patients of group B was higher on day 1 than
the reference data (13.5 ± 4.7 pg/ml), but mean levels in
both groups were not significantly higher than the refer-
ence data. CNP concentrations in the CSF decreased
gradually in both groups, but these changes were not sig-
nificant. We also did not observe any significant difference
in the data between the groups.
Discussion
This preliminary study indicated that CNP in CSF could
act as a vasodilator when vasospasms occur in the brain.
However, many test patients showed a higher value of
CNP in the CSF on day 1 than the reference data, and
CNP in the CSF decreased gradually for 1 week, whereas
CNP in the plasma did not change. However, this phe-
nomenon was independent of cerebral vasospasms.
CNP is structurally related to atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP) [9–11]. ANP
and BNP are synthesized predominantly in the
myocardium, whereas CNP is synthesized in the vascular
endothelium. CNP is thought to possess vasodilator
effects on both arteries and veins and has been reported
to act mainly on the vein by increasing the intracellular
cGMP concentration in vascular smooth muscle cells
[12,13]. Both NO and CNP act as a biological messen-
gers and endogenous vasodilators in several different
organs [14]. Suzuki et al showed that NOx levels in the
CSF of SAH patients were markedly higher than the base-
line values of healthy subjects and patients with other neu-
rologic diseases, and NOx increased in patients without
vasospasm but not in patients with vasospasm. They
assumed that a large amount of NO might be produced by
an inducible isoform of NO synthase (iNOS) after SAH
and that this might prevent vasospasm or might have a
suppressive effect [15,16]. CNP induced dose-dependent
vasodilation, but ANP and BNP produced little or no
vasodilation; this suggested that CNP causes significant
vasodilation in cerebral arterioles, an effect thought to be
mediated by a cGMP-dependent mechanism [17].
Previous studies have shown that CNP is the primary bio-
logically active natriuretic peptide in the brain [18]. CNP-
like immunoactivity was detected in human brain,
particularly in the thalamus, hypothalamus, and midbrain
[19], and its levels were 10-fold those of ANP and BNP.
On the basis of these findings, we assumed that CNP in
CSF might have the role of a vasodilator in cerebral arter-
ies. In the present study, plasma CNP levels did not
change during the monitoring period; this was in agree-
ment with the report of Eelco et al [20] who showed that
plasma ANP and BNP levels increased after SAH,
whereas plasma CNP and endothelium CNP were inde-
pendent of ANP and BNP and did not change very much.
We also compared the data with regard to the severity of
the spasm and the outcome but found no correlation.
From our findings, we can say that CNP concentration in
the CSF was high in the acute phase and decreased grad-
ually after SAH, whereas CNP in the plasma did not
change. However, we could not clarify the mechanism of
this phenomenon.
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